These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic relevance of cyclin E expression in operable breast cancer.
    Author: Potemski P, Kusińska R, Pasz-Walczak G, Piekarski JH, Watała C, Płuciennik E, Bednarek AK, Kordek R.
    Journal: Med Sci Monit; 2009 Feb; 15(2):MT34-40. PubMed ID: 19179977.
    Abstract:
    BACKGROUND: Cyclin E is an important regulator of cell-cycle progression. High levels of cyclin E protein in breast cancer have been reported in association with higher disease stage, poor histological differentiation of tumor, and lack of steroid receptors. Data concerning the prognostic relevance of cyclin E expression in breast cancer are conflicting. The aim of this retrospective study was to evaluate the prognostic relevance of cyclin E expression assessed by immunohistochemistry in patients with operable invasive ductal breast cancer. MATERIAL/METHODS: The expression of cyclin E was analyzed by immunostaining in 174 women with breast cancer after radical mastectomy with a median follow-up period of 58 months. Tumor samples were judged to be negative (<2%) or positive (> or =2%) according to the percentage of cells showing the nuclear staining pattern. Ninety-nine (56.9%) tumor samples were regarded as cyclin E-positive. RESULTS: Positive staining for cyclin E determined poor prognosis compared with cyclin E-negative patients in all cases (five-year cancer-specific survival rate of 64.5 vs. 84.5%, p=0.005), in the node-positive group (50.9 vs. 82.1%, p=0.008), and in patients treated with adjuvant chemotherapy (71.0 vs. 96.6%, p=0.008). In a multivariate analysis, high expression of cyclin E was associated with a higher risk of death in the node-positive group (hazard ratio: 3.2, 95%CI: 1.3-8.2, p=0.015). CONCLUSIONS: It was demonstrated that a high expression of cyclin E measured by immunohistochemistry was a significant factor of poor prognosis, especially in the node-positive group.
    [Abstract] [Full Text] [Related] [New Search]